# Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6

> **NCT02480166** · PHASE4 · COMPLETED · sponsor: **Stanford University** · enrollment: 60 (actual)

## Conditions studied

- PT-NANBH

## Interventions

- **DRUG:** 8 weeks SOF/LED
- **DRUG:** 12 weeks SOF/LED

## Key facts

- **NCT ID:** NCT02480166
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02480166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02480166, "Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02480166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*